| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T896 |
0-114 |
Sentence |
denotes |
Drug (Company) Target Original Fragment(s) * Advanced Molecule and Progress in Clinical Trials Techniques Used |
| T897 |
115-245 |
Sentence |
denotes |
Vemurafenib (Plexxikon) [224,226] BRAF-V600E Approved high-concentration biochemical fragment screening, X-ray crystallography |
| T898 |
246-339 |
Sentence |
denotes |
Venetoclax (AbbVie, Genetech) [227,228,229,230] BCL-2 Approved NMR, X-ray crystallography |
| T899 |
340-461 |
Sentence |
denotes |
Ribociclib (Novartis Europharm Limited) [231] CDK4 and 6 Information Not Available Approved Information not Available |
| T900 |
462-594 |
Sentence |
denotes |
PLX3397 (Plexxikon) [232,233,234] FMS, KIT, and FLT3-ITD Phase 3 X-ray crystallography, Structure Confirmed by NMR, MS, and HPLC |
| T901 |
595-697 |
Sentence |
denotes |
Verubecestat (Merck) [235,236] BACE1 Phase 3 NMR, X-ray crystallography, inhibition of cathepsin D |
| T902 |
698-804 |
Sentence |
denotes |
Onalespib (Astex) [237,238] HSP90 Phase 2 X-ray crystallography, isothermal titration calorimetry, NMR |
| T903 |
805-928 |
Sentence |
denotes |
AZD5099 [239,240] Topoisomerase II Phase 1 NMR, Surface Plasmon Resonance, isothermal calorimetry, X-ray cystallography |
| T904 |
929-1015 |
Sentence |
denotes |
AT7519 [241,242,243,244] CDK 1, 2, 4, and 5 Phase 2 NMR, MS, X-ray crystallography |
